About Precigen Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://precigen.com/
Frequently Asked Questions
What is the 52-week range for PGEN?
The 52-week high is $8.98 and the 52-week low is $2.99.
What is the P/E ratio for PGEN?
The P/E ratio data is currently unavailable.
What is the dividend yield for PGEN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -498.32%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -183.98%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 70.73.
Analyst Recommendation Trends
Wall Street analyst consensus for PGEN over the last few months:
Latest PGEN News
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
Here's Why You Should Add URGN Stock to Your Portfolio Now
UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
Precigen's PAPZIMEOS, the first FDA-approved product from AdenoVerse, is now the first-line standard of care for RRP. Read why PGEN stock is a strong buy.
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation.
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
MIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
Precigen, Inc. (NASDAQ:PGEN) announced on September 21 that the FDA granted Platform Technology Designation to AdenoVerse, the technology behind the approved medicine PAPZIMEOS. The designation creates opportunities to reuse manufacturing and preclinical knowledge in future drug applications, potentially reducing work that would otherwise need to be repeated. For Precigen, Inc. (NASDAQ:PGEN), the investment question is […]
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.
LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss
Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?
Precigen (PGEN) is back in focus after the United States Food and Drug Administration granted platform technology designation to its AdenoVerse immunotherapeutic platform, which underpins the recently approved PAPZIMEOS therapy. The recent FDA platform technology designation and the earlier approval of PAPZIMEOS have coincided with a sharp shift in market sentiment toward Precigen, with the share price delivering an 81.07% year-to-date return and a very large 3-year total shareholder return...
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
Precigen (NasdaqGS:PGEN) said the FDA has granted platform technology designation to its AdenoVerse immunotherapeutic platform. The designation applies to the AdenoVerse platform rather than a single drug, covering multiple potential future product candidates across indications. FDA platform technology status can allow certain data and review learnings from one product to support later candidates built on the same backbone. The new FDA platform technology designation for AdenoVerse sits...
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
LLY's Onswik Wins FDA Nod as a Once-Weekly Basal Insulin for T2D
Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.
B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12
B. Riley Securities analyst Yuan Zhi initiates coverage on Precigen (NASDAQ:PGEN) with a Buy rating and announces Price Target of $12.
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.
Vertex Posts Positive Phase II Data on Kidney Disease Drug
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AZN's Trixeo wins EU approval for asthma, adding an indication backed by phase III data showing improved lung function.
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
AstraZeneca's Klygefa wins a positive EU recommendation for AChR-positive gMG, backed by phase III data and a convenient once-weekly treatment option.
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
NVO's Sogroya wins a positive CHMP opinion for idiopathic short stature in the EU, potentially broadening its pediatric growth disorder reach.
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that the United States Food and Drug Administration (FDA) granted platform technology designation to the AdenoVerse® immunotherapeutic platform, which is used in the company's first commercial product, PAPZIMEOS®. The designation reflects the adaptability and potential of the platform to address a broad ran
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback
Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base
Precigen has seen its stock climb sharply in recent years, which naturally puts the focus on what investors are paying for each dollar of its sales. With the share price at US$7.87 at the last close, the open question is whether that level is adequately supported by the company’s current revenue base. Over the past 3 years the stock has returned about 4.6x, which puts a lot of weight on whether its sales profile can carry that kind of re-rating. For a business like Precigen, future outcomes...
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Papzimeos is fueling Precigen's growth, with sales more than doubling sequentially in Q2 and demand continuing to rise in 2026.
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?
Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?
KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.
Here's Why You Should Add RNTX Stock to Your Portfolio Now
Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-23 | Thomasian Harry Jr. | -1 | - | - |
| 2026-09-23 | Thomasian Harry Jr. | -2 | - | - |
| 2026-09-23 | Thomasian Harry Jr. | -42,918 | - | - |
| 2026-09-23 | Thomasian Harry Jr. | -10,744 | - | - |
| 2026-09-23 | Thomasian Harry Jr. | +1 | $1.21 | $1 |
| 2026-09-23 | Thomasian Harry Jr. | +2 | $0.96 | $2 |
| 2026-09-23 | Thomasian Harry Jr. | +42,918 | $2.33 | $99,999 |
| 2026-09-23 | Thomasian Harry Jr. | +10,744 | $4.72 | $50,712 |
| 2026-08-26 | KINDLER JEFFREY B | -185,000 | $7.44 | $1,376,400 |
| 2026-08-25 | Shah Rutul R | -15,342 | - | - |
| 2026-08-25 | Shah Rutul R | -15,342 | $7.5 | $115,065 |
| 2026-08-25 | Shah Rutul R | +15,342 | $2.33 | $35,747 |
| 2026-08-25 | Tennant Phil | -79,166 | - | - |
| 2026-08-25 | Tennant Phil | -79,166 | $7.5 | $593,745 |
| 2026-08-25 | Tennant Phil | +79,166 | $1.61 | $127,457 |
| 2026-08-23 | Lehr Donald P. | -5,208 | - | - |
| 2026-08-23 | Lehr Donald P. | -2,488 | $7.2 | $17,914 |
| 2026-08-23 | Lehr Donald P. | +5,208 | - | - |
| 2026-08-23 | Thomasian Harry Jr. | -7,291 | - | - |
| 2026-08-23 | Thomasian Harry Jr. | -3,577 | $7.2 | $25,754 |
| 2026-08-23 | Thomasian Harry Jr. | +7,291 | - | - |
| 2026-08-23 | Shah Rutul R | -7,500 | - | - |
| 2026-08-23 | Shah Rutul R | -3,647 | $7.2 | $26,258 |
| 2026-08-23 | Shah Rutul R | +7,500 | - | - |
| 2026-08-23 | Tennant Phil | -5,208 | - | - |
| 2026-08-23 | Tennant Phil | -2,585 | $7.2 | $18,612 |
| 2026-08-23 | Tennant Phil | +5,208 | - | - |
| 2026-08-23 | Sabzevari Helen | -20,833 | - | - |
| 2026-08-23 | Sabzevari Helen | -10,184 | $7.2 | $73,325 |
| 2026-08-23 | Sabzevari Helen | +20,833 | - | - |
| 2026-08-21 | Shah Rutul R | -34,658 | - | - |
| 2026-08-21 | Shah Rutul R | -34,658 | $7.5 | $259,935 |
| 2026-08-21 | Shah Rutul R | +34,658 | $2.33 | $80,753 |
| 2026-08-21 | AGEE NANCY H | +3,411 | $7.23 | $24,662 |
| 2026-08-06 | Shah Rutul R | -32,739 | $6.86 | $224,590 |
| 2026-08-03 | Shah Rutul R | -33,772 | - | - |
| 2026-08-03 | Shah Rutul R | -33,772 | $6.5 | $219,518 |
| 2026-08-03 | Shah Rutul R | +33,772 | $2.33 | $78,689 |
| 2026-07-31 | Thomasian Harry Jr. | -100,000 | $6.06 | $606,000 |
| 2026-07-01 | Thomasian Harry Jr. | -171,429 | $5.53 | $948,002 |
| 2026-06-29 | Thomasian Harry Jr. | -28,571 | $5.78 | $165,140 |
| 2026-06-29 | Shah Rutul R | -42,924 | - | - |
| 2026-06-29 | Shah Rutul R | -42,924 | $5.85 | $251,105 |
| 2026-06-29 | Shah Rutul R | +42,924 | $2.33 | $100,013 |
| 2026-06-29 | Sabzevari Helen | -346,836 | - | - |
| 2026-06-29 | Sabzevari Helen | -346,836 | $5.89 | $2,042,864 |
| 2026-06-29 | Sabzevari Helen | +346,836 | $2.33 | $808,128 |
| 2026-05-28 | Thomasian Harry Jr. | -41,884 | $4.36 | $182,614 |
| 2026-05-28 | Tennant Phil | -30,272 | $4.36 | $131,986 |
| 2026-05-28 | Shah Rutul R | -42,703 | $4.36 | $186,185 |
| 2026-05-28 | Lehr Donald P. | -29,131 | $4.36 | $127,011 |
| 2026-05-28 | Sabzevari Helen | -119,250 | $4.36 | $519,930 |
| 2026-05-23 | Thomasian Harry Jr. | -87,500 | - | - |
| 2026-05-23 | Thomasian Harry Jr. | +87,500 | - | - |
| 2026-05-23 | Tennant Phil | -62,500 | - | - |
| 2026-05-23 | Tennant Phil | +62,500 | - | - |
| 2026-05-23 | Shah Rutul R | -90,000 | - | - |
| 2026-05-23 | Shah Rutul R | +90,000 | - | - |
| 2026-05-23 | Sabzevari Helen | -250,000 | - | - |
| 2026-05-23 | Sabzevari Helen | +250,000 | - | - |
| 2026-05-23 | Lehr Donald P. | -62,500 | - | - |
| 2026-05-23 | Lehr Donald P. | +62,500 | - | - |
| 2026-04-20 | Lehr Donald P. | +107,000 | - | - |
| 2026-04-20 | Lehr Donald P. | +358,000 | - | - |
| 2026-04-20 | Sabzevari Helen | +410,000 | - | - |
| 2026-04-20 | Sabzevari Helen | +1,366,000 | - | - |
| 2026-04-20 | Shah Rutul R | +118,000 | - | - |
| 2026-04-20 | Shah Rutul R | +395,000 | - | - |
| 2026-04-20 | Tennant Phil | +115,000 | - | - |
| 2026-04-20 | Tennant Phil | +385,000 | - | - |
| 2026-04-20 | Thomasian Harry Jr. | +120,000 | - | - |
| 2026-04-20 | Thomasian Harry Jr. | +399,000 | - | - |
| 2026-03-30 | KIRK RANDAL J | -2,334,420 | $3.3 | $7,703,586 |
| 2026-03-30 | KIRK RANDAL J | -23,789 | $3.3 | $78,504 |
| 2026-03-30 | KIRK RANDAL J | -38,976 | $3.3 | $128,621 |
| 2026-03-30 | KIRK RANDAL J | -47,101 | $3.3 | $155,433 |
| 2026-03-30 | KIRK RANDAL J | -168,794 | $3.3 | $557,020 |
| 2026-03-30 | KIRK RANDAL J | -426,199 | $3.3 | $1,406,457 |
| 2026-03-30 | KIRK RANDAL J | -50,797 | $3.3 | $167,630 |
| 2026-03-30 | KIRK RANDAL J | -152,063 | $3.3 | $501,808 |
| 2026-03-30 | KIRK RANDAL J | -370,847 | $3.3 | $1,223,795 |
| 2026-03-30 | KIRK RANDAL J | -50,797 | $3.3 | $167,630 |
| 2026-03-30 | KIRK RANDAL J | -1,108,998 | $3.3 | $3,659,693 |
| 2026-03-18 | Thomasian Harry Jr. | -40,293 | - | - |
| 2026-03-18 | Thomasian Harry Jr. | +40,293 | - | - |
| 2026-03-18 | Thomasian Harry Jr. | +40,293 | - | - |
| 2026-03-18 | Tennant Phil | -42,110 | - | - |
| 2026-03-18 | Tennant Phil | +42,110 | - | - |
| 2026-03-18 | Tennant Phil | +42,110 | - | - |
| 2026-03-18 | Sabzevari Helen | -321,100 | - | - |
| 2026-03-18 | Sabzevari Helen | +321,100 | - | - |
| 2026-03-18 | Sabzevari Helen | +321,100 | - | - |
| 2026-03-18 | Shah Rutul R | -44,495 | - | - |
| 2026-03-18 | Shah Rutul R | +44,495 | - | - |
| 2026-03-18 | Shah Rutul R | +44,495 | - | - |
| 2026-03-18 | Lehr Donald P. | -40,443 | - | - |
| 2026-03-18 | Lehr Donald P. | +40,443 | - | - |
| 2026-03-18 | Lehr Donald P. | +40,443 | - | - |
| 2026-03-13 | Frank Steven | -71,839 | - | - |
| 2026-03-13 | Frank Steven | +71,839 | - | - |
| 2026-03-13 | Gupta Vinita D | -71,839 | - | - |
| 2026-03-13 | Gupta Vinita D | +71,839 | - | - |
| 2026-03-13 | Turley James S | -71,839 | - | - |
| 2026-03-13 | Turley James S | +71,839 | - | - |
| 2026-03-13 | AGEE NANCY H | -71,839 | - | - |
| 2026-03-13 | AGEE NANCY H | +71,839 | - | - |
| 2026-03-13 | ALVAREZ CESAR L | -71,839 | - | - |
| 2026-03-13 | ALVAREZ CESAR L | +71,839 | - | - |
| 2026-03-13 | KINDLER JEFFREY B | -71,839 | - | - |
| 2026-03-13 | KINDLER JEFFREY B | +71,839 | - | - |
| 2026-03-13 | Hassan Fred | -71,839 | - | - |
| 2026-03-13 | Hassan Fred | +71,839 | - | - |
| 2026-03-13 | KIRK RANDAL J | -143,678 | - | - |
| 2026-03-13 | KIRK RANDAL J | +143,678 | - | - |
| 2026-03-10 | KIRK RANDAL J | +82,147 | - | - |
| 2026-03-10 | KIRK RANDAL J | +71,225 | - | - |
| 2026-03-10 | KIRK RANDAL J | +28,490 | $3.51 | $100,000 |
| 2026-03-10 | Turley James S | +41,073 | - | - |
| 2026-03-10 | Turley James S | +35,612 | - | - |
| 2026-03-10 | Turley James S | +17,806 | $3.51 | $62,499 |
| 2026-03-10 | Gupta Vinita D | +41,073 | - | - |
| 2026-03-10 | Gupta Vinita D | +35,612 | - | - |
| 2026-03-10 | Gupta Vinita D | +17,948 | $3.51 | $62,997 |
| 2026-03-10 | Frank Steven | +41,073 | - | - |
| 2026-03-10 | Frank Steven | +35,612 | - | - |
| 2026-03-10 | Frank Steven | +14,245 | $3.51 | $50,000 |
| 2026-03-10 | AGEE NANCY H | +41,073 | - | - |
| 2026-03-10 | AGEE NANCY H | +35,612 | - | - |
| 2026-03-10 | AGEE NANCY H | +16,096 | $3.51 | $56,497 |
| 2026-03-10 | ALVAREZ CESAR L | +41,073 | - | - |
| 2026-03-10 | ALVAREZ CESAR L | +35,612 | - | - |
| 2026-03-10 | ALVAREZ CESAR L | +17,806 | $3.51 | $62,499 |
| 2026-03-10 | KINDLER JEFFREY B | +41,073 | - | - |
| 2026-03-10 | KINDLER JEFFREY B | +35,612 | - | - |
| 2026-03-10 | KINDLER JEFFREY B | +19,658 | $3.51 | $69,000 |
| 2026-03-10 | Hassan Fred | +41,073 | - | - |
| 2026-03-10 | Hassan Fred | +35,612 | - | - |
| 2026-03-10 | Hassan Fred | +17,948 | $3.51 | $62,997 |
| 2025-12-22 | KIRK RANDAL J | -956,200 | $4.18 | $3,996,916 |
| 2025-12-22 | KIRK RANDAL J | -5,958 | $4.18 | $24,904 |
| 2025-12-22 | KIRK RANDAL J | -9,931 | $4.18 | $41,512 |
| 2025-12-22 | KIRK RANDAL J | -11,917 | $4.18 | $49,813 |
| 2025-12-22 | KIRK RANDAL J | -42,702 | $4.18 | $178,494 |
| 2025-12-22 | KIRK RANDAL J | -159,321 | $4.18 | $665,962 |
| 2025-12-22 | KIRK RANDAL J | -12,909 | $4.18 | $53,960 |
| 2025-12-22 | KIRK RANDAL J | -38,729 | $4.18 | $161,887 |
| 2025-12-22 | KIRK RANDAL J | -94,341 | $4.18 | $394,345 |
| 2025-12-22 | KIRK RANDAL J | -12,909 | $4.18 | $53,960 |
| 2025-12-22 | KIRK RANDAL J | -555,119 | $4.18 | $2,320,397 |
| 2025-12-12 | KINDLER JEFFREY B | -235,467 | $3.6349 | $855,899 |
| 2025-11-21 | KIRK RANDAL J | -937,308 | $3.83 | $3,589,890 |
| 2025-11-20 | KIRK RANDAL J | -942,832 | $4.08 | $3,846,755 |
| 2025-11-19 | KIRK RANDAL J | -1,086,153 | $4.47 | $4,855,104 |